Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated with Treatment Resistance: Tumor Habitat Analysis Using Physiologic MRI

References

1. 1.↵
   1. Cai Q,
   2. Fang Y,
   3. Young KH

   . Primary central nervous system lymphoma: molecular pathogenesis and advances in treatment. Transl Oncol 2019;12:523–38 doi:10.1016/j.tranon.2018.11.011 pmid:30616219

   CrossRefPubMed
2. 2.↵
   1. Fowler NH,
   2. Cheah CY,
   3. Gascoyne RD, et al

   . Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 2016;101:531–40 doi:10.3324/haematol.2015.139493 pmid:27132279

   Abstract/FREE Full Text
3. 3.↵
   1. Alame M,
   2. Pirel M,
   3. Costes-Martineau V, et al

   . Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. Virchows Arch 2020;476:891–902 doi:10.1007/s00428-019-02695-6 pmid:31811434

   CrossRefPubMed
4. 4.↵
   1. Scott DW,
   2. Gascoyne RD

   . The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014;14:517–34 doi:10.1038/nrc3774 pmid:25008267

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Lenz G,
   2. Dreyling M,
   3. Hoster E, et al

   . Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–92 doi:10.1200/JCO.2005.08.133 pmid:15668467

   Abstract/FREE Full Text
6. 6.↵
   1. Nayak L,
   2. Batchelor TT

   . Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol 2013;14:539–52 doi:10.1007/s11864-013-0252-6 pmid:23934511

   CrossRefPubMed
7. 7.↵
   1. Chung SR,
   2. Choi YJ,
   3. Kim HS, et al

   . Tumor vascular permeability pattern is associated with complete response in immunocompetent patients with newly diagnosed primary central nervous system lymphoma: retrospective cohort study. Medicine 2016;95:e2624 doi:10.1097/MD.0000000000002624 pmid:26871782

   CrossRefPubMed
8. 8.↵
   1. Hatzoglou V,
   2. Oh JH,
   3. Buck O, et al

   . Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma. J Neurooncol 2018;140:351–58 doi:10.1007/s11060-018-2960-z pmid:30073640

   CrossRefPubMed
9. 9.↵
   1. Kim M,
   2. Kim HS

   . Emerging techniques in brain tumor imaging: what radiologists need to know. Korean J Radiol 2016;17:598–619 doi:10.3348/kjr.2016.17.5.598 pmid:27587949

   CrossRefPubMed
10. 10.↵
    1. Provenzale JM,
    2. Mukundan S,
    3. Barboriak DP

    . Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006;239:632–49 doi:10.1148/radiol.2393042031 pmid:16714455

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Barajas RF Jr.,
    2. Rubenstein JL,
    3. Chang JS, et al

    . Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010;31:60–66 doi:10.3174/ajnr.A1750 pmid:19729544

    Abstract/FREE Full Text
12. 12.↵
    1. O'Connor JP,
    2. Rose CJ,
    3. Waterton JC, et al

    . Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res 2015;21:249–57 doi:10.1158/1078-0432.CCR-14-0990 pmid:25421725

    Abstract/FREE Full Text
13. 13.↵
    1. Oken MM,
    2. Creech RH,
    3. Tormey DC, et al

    . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55 doi:10.1097/00000421-198212000-00014 pmid:7165009

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Abrey LE,
    2. Batchelor TT,
    3. Ferreri AJ, et al

    ; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–43 doi:10.1200/JCO.2005.13.524 pmid:15955902

    Abstract/FREE Full Text
15. 15.↵
    1. Wen PY,
    2. Macdonald DR,
    3. Reardon DA, et al

    . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

    Abstract/FREE Full Text
16. 16.↵
    1. Ferreri AJ,
    2. Blay JY,
    3. Reni M, et al

    . Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266–72 doi:10.1200/JCO.2003.09.139 pmid:12525518

    Abstract/FREE Full Text
17. 17.↵
    1. Thurnher MM,
    2. Rieger A,
    3. Kleibl-Popov C, et al

    . Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings. Neuroradiology 2001;43:29–35 doi:10.1007/s002340000480 pmid:11214644

    CrossRefPubMed
18. 18.↵
    1. Isensee F,
    2. Jaeger PF,
    3. Kohl SA, et al

    . nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods 2021;18:203–11 doi:10.1038/s41592-020-01008-z pmid:33288961

    CrossRefPubMed
19. 19.↵
    1. Erickson GJ,
    2. Smith CR

    1. Gull SF

    . Bayesian inductive inference and maximum entropy. In: Erickson GJ, Smith CR, eds. Maximum-Entropy and Bayesian Methods in Science and Engineering: Fundamental Theories of Physics (An International Book Series on The Fundamental Theories of Physics: Their Clarification, Development and Application), vol 31-32. Springer-Verlag Netherlands; 1988:53–74
20. 20.↵
    1. Ingrisch M,
    2. Schneider MJ,
    3. Norenberg D, et al

    . Radiomic analysis reveals prognostic information in T1-weighted baseline magnetic resonance imaging in patients with glioblastoma. Invest Radiol 2017;52:360–66 doi:10.1097/RLI.0000000000000349 pmid:28079702

    CrossRefPubMed
21. 21.↵
    1. Han K,
    2. Song K,
    3. Choi BW

    . How to develop, validate, and compare clinical prediction models involving radiological parameters: study design and statistical methods. Korean J Radiol 2016;17:339–50 doi:10.3348/kjr.2016.17.3.339 pmid:27134523

    CrossRefPubMed
22. 22.↵
    1. D'agostino RB,
    2. Nam BH

    . Evaluation of the performance of survival analysis models: discrimination and calibration measures. Advances in Survival Analysis 2003;23:1–25
23. 23.↵
    1. Africa E,
    2. Pauciulo A,
    3. Vadalà R, et al

    . Primary central nervous system lymphoma: role of DWI in the differential diagnosis. Rays 2005;30:221–26 pmid:16512067

    PubMed
24. 24.↵
    1. Guo AC,
    2. Cummings TJ,
    3. Dash RC, et al

    . Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177–83 doi:10.1148/radiol.2241010637 pmid:12091680

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Herneth AM,
    2. Guccione S,
    3. Bednarski M

    . Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 2003;45:208–13 doi:10.1016/s0720-048x(02)00310-8 pmid:12595105

    CrossRefPubMed
26. 26.↵
    1. Khayal IS,
    2. Vandenberg SR,
    3. Smith KJ, et al

    . MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol 2011;13:1192–201 doi:10.1093/neuonc/nor122 pmid:21865401

    CrossRefPubMed
27. 27.↵
    1. Wu X,
    2. Kellokumpu-Lehtinen PL,
    3. Pertovaara H, et al

    . Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma–a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography. NMR Biomed 2011;24:1181–90 doi:10.1002/nbm.1689 pmid:21387451

    CrossRefPubMed
28. 28.↵
    1. Yetkin FZ,
    2. Mendelsohn D

    . Hypoxia imaging in brain tumors. Neuroimaging Clin N Am 2002;12:537–52 doi:10.1016/S1052-5149(02)00029-1 pmid:12687910

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Le Duc G,
    2. Péoc’h M,
    3. Rémy C, et al

    . Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain. Magn Reson Med 1999;42:754–61 doi:10.1002/(sici)1522-2594(199910)42:4<754::aid-mrm18>3.0.co;2-q pmid:10502765

    CrossRefPubMed
30. 30.↵
    1. Knisely JP,
    2. Rockwell S

    . Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin N Am 2002;12:525–36 doi:10.1016/S1052-5149(02)00032-1 pmid:12687909

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Valles FE,
    2. Perez-Valles CL,
    3. Regalado S, et al

    . Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol 2013;34:35–40 doi:10.3174/ajnr.A3165 pmid:22936096

    Abstract/FREE Full Text
32. 32.↵
    1. Buttini M,
    2. Appel K,
    3. Sauter A, et al

    . Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience 1996;71:1–16 doi:10.1016/0306-4522(95)00414-9 pmid:8834388

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Zazulia AR,
    2. Diringer MN,
    3. Videen TO, et al

    . Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab 2001;21:804–10 doi:10.1097/00004647-200107000-00005 pmid:11435792

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Kim SK,
    2. Park JE,
    3. Kim KH

    , KSNO Guideline Working Group, et al. A national consensus survey for current practice in brain tumor management, III: brain metastasis and primary central nervous system lymphoma. Brain Tumor Res Treat 2020;8:20–28 doi:10.14791/btrt.2020.8.e7 pmid:32390350

    CrossRefPubMed